Transforming the early detection of heart disease through AI-ECG solutions

Millions of ECGs are performed every week, however, for decades these tests have largely remained unchanged. Conventional ECGs are easy and quick to perform, but unfortunately do not detect most heart disease conditions.

Artificial Intelligence-Enhanced Electrocardiography (AI-ECG) is set to transform cardiovascular medicine. AI-ECG allows previously unseen disease to be identified and radically expands the clinical usefulness of an ECG.

Heart disease is the leading cause of death

for men, women, and people of most racial and ethnic groups*

Heart disease is the leading cause of death

Known as the silent killer, heart attacks can occur unexpectedly, and heart disease symptoms often do not appear until an acute stage.*

AI-ECG provides frontline healthcare with more effective diagnoses and referrals, ensuring earlier treatment and better outcomes.

1 in 5 heart attacks are silent – the damage is done, 
but the person is not aware of it.

Every 36 seconds, one person dies from 
cardiovascular disease**
Every 40 seconds, one person in the US suffers 
from a heart attack**
80% of heart disease cases could be prevented**

19.9 million deaths from cardiovascular disease (CVD)
 in 2021***

* Center for Disease Control and Prevention. Heart Disease Facts

** The Center for Advancing Health (CFAH). Heart Disease Statistics in the US (2024 Update)

*** American Heart Association. 2024 Heart Disease and Stroke Statistics Update Fact Sheet

Our Solutions

HeartSciences is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting worldwide, either via our MyoVista Insights™ cloud-platform using one of the millions of ECG devices currently in clinical use or via our MyoVista® wavECG™ Device.
  • One of the world’s largest commercial portfolios of AI-ECG algorithms.
  • Covering a wide range of cardiovascular conditions.
  • Extensive clinical publications.

Our Products

MyoVista-InsightsLogo Options
  • Cloud-based AI-ECG algorithms delivered using existing ECG devices.
  • Covering a range of important cardiovascular conditions.
  • Integrating seamlessly with existing clinical pathways.
MyoVista-Logo-4color-CMYK
  • AI-ECG algorithm incorporated directly into the device.
  • High-performance upgraded 12-lead resting ECG utilizing proprietary signal processing technology.
  • Conventional ECG results provided in the same test.

Our Solutions

HeartSciences is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting worldwide, either via our MyoVista Insights™ cloud-platform using one of the millions of ECG devices currently in clinical use or via our MyoVista® wavECG™ Device.
  • One of the world’s largest commercial portfolios of AI-ECG algorithms.
  • Covering a wide range of cardiovascular conditions.
  • Extensive clinical publications.

Our Products

  • Cloud-based AI-ECG algorithms delivered using existing ECG devices.
  • Covering a range of important cardiovascular conditions.
  • Integrating seamlessly with existing clinical pathways.
  • AI-ECG algorithm incorporated directly into the device.
  • High-performance upgraded 12-lead resting ECG utilizing proprietary signal processing technology.
  • Conventional ECG results provided in the same test

Latest News

Clinical publications